Pharmafile Logo
Pharmafocus logo
Advanced Search

Biocon Biologics

Showing 1 posts of 1 posts found.

Biocon Biologics gains EU approval for bone health therapies

July 4, 2025
Market Access, Medical Communications, Research and Development Biocon Biologics, Committee for Medicinal Products for Human USE, European Commission, Evfraxy, Oncology, Orthopaedics, Osteoporosis, Vevzuo, bone health, osteoporosis, prostate cancer

Biocon Biologics has announced that the European Commission has granted marketing authorisation for its denosumab biosimilars, Vevzuo and Evfraxy, marking …

News
The Gateway to Local Adoption Series

Latest content

Product value to pathway impact: What the CVD Modern Service Framework means for pharma

August 9, 2026

Functional lung imaging offers new possibilities for respiratory care

August 9, 2026

Five Facts about cardiovascular disease

August 9, 2026

Data integrity: the keystone for AI adoption, patient safety and organisational reputation

August 9, 2026

Artificial hearts: a century of innovation

August 9, 2026